CY1109832T1 - Επεξεργασια τρυγικης φορμοτερολης και πολυμορφο - Google Patents

Επεξεργασια τρυγικης φορμοτερολης και πολυμορφο

Info

Publication number
CY1109832T1
CY1109832T1 CY20101100073T CY101100073T CY1109832T1 CY 1109832 T1 CY1109832 T1 CY 1109832T1 CY 20101100073 T CY20101100073 T CY 20101100073T CY 101100073 T CY101100073 T CY 101100073T CY 1109832 T1 CY1109832 T1 CY 1109832T1
Authority
CY
Cyprus
Prior art keywords
treatment
multiplorm
triumph
polymorph
formoterol
Prior art date
Application number
CY20101100073T
Other languages
Greek (el)
English (en)
Inventor
Gerald J Tanoury
Chris H Senanayake
Donald W Kessler
Original Assignee
Sepracor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21892899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109832(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor Inc. filed Critical Sepracor Inc.
Publication of CY1109832T1 publication Critical patent/CY1109832T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
CY20101100073T 2001-11-09 2010-01-22 Επεξεργασια τρυγικης φορμοτερολης και πολυμορφο CY1109832T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/037,183 US6472563B1 (en) 2001-11-09 2001-11-09 Formoterol tartrate process and polymorph
EP02786502A EP1446380B1 (en) 2001-11-09 2002-10-23 Formoterol tartrate process and polymorph

Publications (1)

Publication Number Publication Date
CY1109832T1 true CY1109832T1 (el) 2014-09-10

Family

ID=21892899

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100073T CY1109832T1 (el) 2001-11-09 2010-01-22 Επεξεργασια τρυγικης φορμοτερολης και πολυμορφο

Country Status (13)

Country Link
US (10) US6472563B1 (https=)
EP (3) EP1446380B1 (https=)
JP (1) JP4271574B2 (https=)
AT (1) ATE450497T1 (https=)
AU (2) AU2002349914B2 (https=)
CA (1) CA2477642C (https=)
CY (1) CY1109832T1 (https=)
DE (1) DE60234629D1 (https=)
DK (1) DK1446380T3 (https=)
ES (2) ES2685100T3 (https=)
PT (1) PT1446380E (https=)
SI (1) SI1446380T1 (https=)
WO (1) WO2003042165A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472563B1 (en) * 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
WO2005019227A1 (en) * 2003-08-22 2005-03-03 Orchid Chemicals & Pharmaceuticals Ltd Process for the preparation of cephalosporin antibiotic
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20060160841A1 (en) * 2005-01-19 2006-07-20 Chenkou Wei Crystallization via high-shear transformation
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US7718822B2 (en) * 2007-08-28 2010-05-18 Sepracor Inc. Carbamate Stereoisomer
US8501994B2 (en) * 2007-08-28 2013-08-06 Sunovion Pharmaceuticals Inc. Acetamide stereoisomer
CN101393186A (zh) * 2007-09-21 2009-03-25 北京德众万全药物技术开发有限公司 一种hplc法分离分析酒石酸福莫特罗手性异构体的方法
GB2468073B (en) * 2008-02-26 2012-09-05 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
WO2009106997A2 (en) * 2008-02-28 2009-09-03 Actavis Group Ptc Ehf Amorphous arformoterol l-(+)-tartrate
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
WO2010128355A2 (en) 2008-12-26 2010-11-11 Actavis Group Ptc Ehf Improved processes for preparing substantially pure arformoterol and its intermediates
RS53514B1 (sr) * 2009-10-02 2015-02-27 Chiesi Farmaceutici S.P.A. Farmaceutske aerosolne formulacije od formoterola i beklometazon dipropionata
IT1399912B1 (it) * 2010-04-29 2013-05-09 Lundbeck Pharmaceuticals Italy S Pa Processo di preparazione di ritodrina cloridrato.
SMT202100546T1 (it) 2011-09-19 2021-11-12 Orexo Ab Compresse per via sublinguale resistenti all'abuso comprendenti buprenorfina e naloxone
CN104220420B (zh) * 2012-03-12 2016-08-31 利斯维实验室有限公司 一种长效β-2肾上腺素受体激动剂的新型多晶
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
EP3473615B1 (en) 2013-02-28 2022-01-19 Journey Medical Corporation Glycopyrrolate salts
EP2997009A4 (en) * 2013-05-17 2017-01-18 Glenmark Pharmaceuticals Limited Process for the preparation of arformoterol or salt thereof
CN107151219A (zh) * 2017-05-23 2017-09-12 北京万全德众医药生物技术有限公司 酒石酸阿福特罗的精制方法
CN111909049B (zh) * 2020-09-03 2023-04-25 扬州中宝药业股份有限公司 一种酒石酸阿福特罗精制的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2005492A6 (es) 1987-12-23 1989-03-01 Lasa Lab Procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2((2- (4-metoxifenil)-1metiletil)amino)etil)fenil)foramida (i).
ES2031407A6 (es) 1988-10-05 1992-12-01 Lasa Lab Mejoras introducidas en el objeto de la patente principal n{ 8703715 por: procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2-((2-(4-metoxifenil)-1-metiletil)amino)etil)fenil)formamida".
SE8901060D0 (sv) 1989-03-28 1989-03-28 Draco Ab New compounds
US5434304A (en) * 1990-09-26 1995-07-18 Aktiebolaget Astra Process for preparing formoterol and related compounds
SE9003057D0 (sv) 1990-09-26 1990-09-26 Astra Ab New process
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
CN1150890C (zh) * 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
US6472563B1 (en) * 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph

Also Published As

Publication number Publication date
AU2008253696A1 (en) 2009-01-08
US20080114187A1 (en) 2008-05-15
ES2336436T3 (es) 2010-04-13
US20060264507A1 (en) 2006-11-23
US20090156862A1 (en) 2009-06-18
ATE450497T1 (de) 2009-12-15
WO2003042165A1 (en) 2003-05-22
US6720453B2 (en) 2004-04-13
CA2477642C (en) 2014-02-11
US20100249459A1 (en) 2010-09-30
US20100204336A1 (en) 2010-08-12
CA2477642A1 (en) 2003-05-22
EP1446380B1 (en) 2009-12-02
US20030149304A1 (en) 2003-08-07
EP2305635A3 (en) 2011-07-20
EP2305635A2 (en) 2011-04-06
PT1446380E (pt) 2010-01-07
DE60234629D1 (de) 2010-01-14
US20120108670A1 (en) 2012-05-03
US7732641B2 (en) 2010-06-08
US20050148667A1 (en) 2005-07-07
US7145036B2 (en) 2006-12-05
EP1446380A1 (en) 2004-08-18
DK1446380T3 (da) 2010-01-04
EP2305635B1 (en) 2018-06-13
US6472563B1 (en) 2002-10-29
US20040176450A1 (en) 2004-09-09
AU2008253696B2 (en) 2012-04-12
JP2005509025A (ja) 2005-04-07
US7964753B2 (en) 2011-06-21
EP2165999A1 (en) 2010-03-24
SI1446380T1 (sl) 2010-03-31
US7342132B2 (en) 2008-03-11
AU2002349914B2 (en) 2008-09-04
US7479572B2 (en) 2009-01-20
ES2685100T3 (es) 2018-10-05
US8110706B2 (en) 2012-02-07
JP4271574B2 (ja) 2009-06-03

Similar Documents

Publication Publication Date Title
CY1109832T1 (el) Επεξεργασια τρυγικης φορμοτερολης και πολυμορφο
BR0314688A (pt) Novos derivados de piperidina para utilização no tratamento de estados de doença mediados pela quimiocina
NO20040100L (no) Nye forbindelser som anti-inflammasjons, immunmodulerende og anti-proliferative midler
LU92520I2 (fr) Bédaquiline, ou son sel d'addition d'acide ou de base pharmaceutiquement acceptable, y compris le fumarate de bédaquiline
EP1801106A3 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
DE60140973D1 (de) Kristallines und reines Modafinil und Verfahren zu seiner Herstellung
SE0104332D0 (sv) Therapeutic agents
CY1108808T1 (el) Ενωσεις μοτιλιδης
EA200301276A1 (ru) Новые производные сульфоновых кислот
NO984195D0 (no) Nye benzofuranonderivater og fremgangsmåte for fremstilling derav
EA200301120A1 (ru) Цитрат 5,8,14-триазатетрацикло (10.3.1.0.0)-гексадека-2 (11),3,5,7,9-пентаена
IT1319234B1 (it) Processo di preparazione di gabapentina.
NO20050612L (no) Pyrrolidinderivater som oksytocinantagonister
NO20042681L (no) Ny krystallinsk polymorf av venlafaxine-hydroklorid og fremgangsmater for fremstilling derav
ATE277887T1 (de) Verfahren zur herstellung von 1,4-bis((2- (dimethylamino)ethyl amino)-5,8- dihydroxyanthracene-9,10-dion
NO995676L (no) Isoftalamid derivat som gul polymorf
BR0116721A (pt) Processo para a preparação de (±)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperi dina
DE50003759D1 (de) Verfahren zur herstellung von n-(4,5-bis-methansulfonyl-2-methyl-benzoyl)-guanidin, hydrochlorid
IL153784A0 (en) Novel n-(2-phenyl-3-aminopropyl) naphthamides
DK0709378T3 (da) Aminoalkyloximer, en fremgangsmåde til deres fremstilling, deres anvendelse som lægemidler og mellemproduktforbindelser
PT1317427E (pt) Processo para a producao de compostos quirais
DE60235119D1 (en) Bipyridinylderivate als hochselektive cyclooxygenase-2-inhibitoren
TH106299A (th) เฟนิลพิเพอราซีนชนิดใหม่
TH61587A (https=)
TH64671A (th) ฟลูออโรเบนซาไมด์